These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32918955)

  • 1. RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.
    Chan LK; Ho DW; Kam CS; Chiu EY; Lo IL; Yau DT; Cheung ET; Tang CN; Tang VW; Lee TK; Wong CC; Chok KS; Chan AC; Cheung TT; Wong CM; Ng IO
    J Hepatol; 2021 Feb; 74(2):360-371. PubMed ID: 32918955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B Virus X Protein Modulates p90 Ribosomal S6 Kinase 2 by ERK to Promote Growth of Hepatoma Cells.
    Han N; Zhang Q; Tang X; Bai L; Yan L; Tang H
    Viruses; 2023 May; 15(5):. PubMed ID: 37243268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
    Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
    Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.
    Liao X; Bu Y; Jiang S; Chang F; Jia F; Xiao X; Song G; Zhang M; Ning P; Jia Q
    Hepatol Int; 2019 Jul; 13(4):440-453. PubMed ID: 31250351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis.
    Schaeffer S; Gupta B; Calatayud AL; Calderaro J; Caruso S; Hirsch TZ; Pelletier L; Zucman-Rossi J; Rebouissou S
    J Hepatol; 2023 Sep; 79(3):704-716. PubMed ID: 37201672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
    Kim YS; Lee YM; Oh TI; Shin DH; Kim GH; Kan SY; Kang H; Kim JH; Kim BM; Yim WJ; Lim JH
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
    Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
    Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma.
    Mok EHK; Leung CON; Zhou L; Lei MML; Leung HW; Tong M; Wong TL; Lau EYT; Ng IOL; Ding J; Yun JP; Yu J; Zhu HL; Lin CH; Lindholm D; Leung KS; Cybulski JD; Baker DM; Ma S; Lee TKW
    Cancer Res; 2022 Sep; 82(17):3102-3115. PubMed ID: 35767704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
    Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPARC Stabilizes ApoE to Induce Cholesterol-Dependent Invasion and Sorafenib Resistance in Hepatocellular Carcinoma.
    Wan S; He QY; Yang Y; Liu F; Zhang X; Guo X; Niu H; Wang Y; Liu YX; Ye WL; Li XM; ZhuanSun XM; Sun P; He XS; Hu G; Breuhahn K; Zhao H; Wu GQ; Wu H
    Cancer Res; 2024 Jun; 84(11):1872-1888. PubMed ID: 38471084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
    Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway.
    Zhou Q; Huang T; Jiang Z; Ge C; Chen X; Zhang L; Zhao F; Zhu M; Chen T; Cui Y; Li H; Yao M; Li J; Tian H
    Oncogene; 2020 Mar; 39(10):2140-2155. PubMed ID: 31819169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
    Hu C; Li W; Tian F; Jiang K; Liu X; Cen J; He Q; Qiu Z; Kienast Y; Wang Z; Zhang H; Ji Y; Hu J; Hui L
    J Hepatol; 2018 Mar; 68(3):465-475. PubMed ID: 29113912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
    J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma.
    Lin X; Li AM; Li YH; Luo RC; Zou YJ; Liu YY; Liu C; Xie YY; Zuo S; Liu Z; Liu Z; Fang WY
    Signal Transduct Target Ther; 2020 Feb; 5(1):13. PubMed ID: 32296025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.
    Qiu Q; Jiang J; Lin L; Cheng S; Xin D; Jiang W; Shen J; Hu Z
    Int J Oncol; 2016 Jun; 48(6):2508-20. PubMed ID: 27082640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis.
    Li D; Jin L; Alesi GN; Kim YM; Fan J; Seo JH; Wang D; Tucker M; Gu TL; Lee BH; Taunton J; Magliocca KR; Chen ZG; Shin DM; Khuri FR; Kang S
    J Biol Chem; 2013 Nov; 288(45):32528-32538. PubMed ID: 24085294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.